{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T14:12:26Z","timestamp":1761919946651},"reference-count":31,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2015,5,1]],"date-time":"2015-05-01T00:00:00Z","timestamp":1430438400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100005189","name":"Leukemia and Lymphoma Society","doi-asserted-by":"publisher","award":["P01 CA095426"],"award-info":[{"award-number":["P01 CA095426"]}],"id":[{"id":"10.13039\/100005189","id-type":"DOI","asserted-by":"publisher"}]},{"name":"D Warren Brown Foundation"}],"content-domain":{"domain":["lrjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2015,5]]},"DOI":"10.1016\/j.leukres.2015.02.001","type":"journal-article","created":{"date-parts":[[2015,2,7]],"date-time":"2015-02-07T18:06:50Z","timestamp":1423332410000},"page":"495-500","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":45,"title":["Final results of EFC6663: A multicenter, international, phase 2 study of alvocidib for patients with fludarabine-refractory chronic lymphocytic leukemia"],"prefix":"10.1016","volume":"39","author":[{"given":"Mark C.","family":"Lanasa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leslie","family":"Andritsos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer R.","family":"Brown","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Janice","family":"Gabrilove","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Federico","family":"Caligaris-Cappio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paolo","family":"Ghia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard A.","family":"Larson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas J.","family":"Kipps","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Veronique","family":"Leblond","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donald W.","family":"Milligan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ann","family":"Janssens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amy J.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nyla A.","family":"Heerema","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas","family":"B\u00fchler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephan","family":"Stilgenbauer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeanne","family":"Devin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Hallek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John C.","family":"Byrd","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael R.","family":"Grever","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.leukres.2015.02.001_bib0160","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1056\/NEJMra041720","article-title":"Chronic lymphocytic leukemia","volume":"352","author":"Chiorazzi","year":"2005","journal-title":"Engl N J Med"},{"key":"10.1016\/j.leukres.2015.02.001_bib0165","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1016\/S0140-6736(08)60456-0","article-title":"Chronic lymphocytic leukaemia","volume":"371","author":"Dighiero","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.leukres.2015.02.001_bib0170","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1080\/1042819021000006547","article-title":"Results of first salvage therapy for patients refractory to a fludarabine regimen in chronic lymphocytic leukemia","volume":"43","author":"Keating","year":"2002","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.leukres.2015.02.001_bib0175","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.1002\/cncr.0680","article-title":"Frequency and type of serious infections in fludarabine-refractory B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma: implications for clinical trials in this patient population","volume":"94","author":"Perkins","year":"2002","journal-title":"Cancer"},{"key":"10.1016\/j.leukres.2015.02.001_bib0180","doi-asserted-by":"crossref","first-page":"2824","DOI":"10.1002\/cncr.24329","article-title":"Treatment of fludarabine-refractory chronic lymphocytic leukemia","volume":"115","author":"Tsimberidou","year":"2009","journal-title":"Cancer"},{"key":"10.1016\/j.leukres.2015.02.001_bib0185","doi-asserted-by":"crossref","first-page":"3554","DOI":"10.1182\/blood.V99.10.3554","article-title":"Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study","volume":"99","author":"Keating","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2015.02.001_bib0190","doi-asserted-by":"crossref","first-page":"3994","DOI":"10.1200\/JCO.2008.21.1128","article-title":"Subcutaneous alemtuzumab in fludarabine-refractory chronic lymphocytic leukemia: clinical results and prognostic marker analyses from the CLL2H study of the German Chronic Lymphocytic Leukemia Study Group","volume":"27","author":"Stilgenbauer","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.leukres.2015.02.001_bib0195","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1200\/JCO.2009.25.3187","article-title":"Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia","volume":"28","author":"Wierda","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.leukres.2015.02.001_bib0200","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1006\/bbrc.1994.1742","article-title":"Potent inhibition of CDC2 kinase activity by the flavonoid L86-8275","volume":"201","author":"Losiewicz","year":"1994","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.leukres.2015.02.001_bib0205","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1093\/jnci\/84.22.1736","article-title":"Growth inhibition with reversible cell cycle arrest of carcinoma cells by flavone L86-8275","volume":"84","author":"Kaur","year":"1992","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.leukres.2015.02.001_bib0210","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1182\/blood.V96.2.393","article-title":"Protein kinase inhibitors flavopiridol and 7-hydroxy-staurosporine down-regulate antiapoptosis proteins in B-cell chronic lymphocytic leukemia","volume":"96","author":"Kitada","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2015.02.001_bib0215","doi-asserted-by":"crossref","first-page":"3804","DOI":"10.1182\/blood.V92.10.3804","article-title":"Flavopiridol induces apoptosis in chronic lymphocytic leukemia cells via activation of caspase-3 without evidence of bcl-2 modulation or dependence on functional p53","volume":"92","author":"Byrd","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2015.02.001_bib0220","doi-asserted-by":"crossref","first-page":"4307","DOI":"10.1182\/blood.V90.11.4307","article-title":"The novel cyclin-dependent kinase inhibitor flavopiridol downregulates Bcl-2 and induces growth arrest and apoptosis in chronic B-cell leukemia lines","volume":"90","author":"Konig","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2015.02.001_bib0225","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1016\/j.leukres.2005.03.010","article-title":"Flavopiridol administered as a 24-hour continuous infusion in chronic lymphocytic leukemia lacks clinical activity","volume":"29","author":"Flinn","year":"2005","journal-title":"Leuk Res"},{"key":"10.1016\/j.leukres.2015.02.001_bib0230","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1080\/10428190290016908","article-title":"Seventy-two hour continuous infusion flavopiridol in relapsed and refractory mantle cell lymphoma","volume":"43","author":"Lin","year":"2002","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.leukres.2015.02.001_bib0235","doi-asserted-by":"crossref","first-page":"2157","DOI":"10.1200\/JCO.2002.08.080","article-title":"Phase I study of the cyclin-dependent kinase inhibitor flavopiridol in combination with paclitaxel in patients with advanced solid tumors","volume":"20","author":"Schwartz","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.leukres.2015.02.001_bib0240","first-page":"1590","article-title":"A phase II trial of the cyclin-dependent kinase inhibitor flavopiridol in patients with previously untreated stage IV non-small cell lung cancer","volume":"7","author":"Shapiro","year":"2001","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.leukres.2015.02.001_bib0245","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1182\/blood-2006-05-020735","article-title":"Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia","volume":"109","author":"Byrd","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2015.02.001_bib0250","doi-asserted-by":"crossref","first-page":"2637","DOI":"10.1182\/blood-2008-07-168583","article-title":"Clinical response and pharmacokinetics from a phase 1 study of an active dosing schedule of flavopiridol in relapsed chronic lymphocytic leukemia","volume":"113","author":"Phelps","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2015.02.001_bib0255","doi-asserted-by":"crossref","first-page":"6012","DOI":"10.1200\/JCO.2009.22.6944","article-title":"Phase II study of flavopiridol in relapsed chronic lymphocytic leukemia demonstrating high response rates in genetically high-risk disease","volume":"27","author":"Lin","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.leukres.2015.02.001_bib0260","doi-asserted-by":"crossref","first-page":"4990","DOI":"10.1182\/blood.V87.12.4990.bloodjournal87124990","article-title":"National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment","volume":"87","author":"Cheson","year":"1996","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2015.02.001_bib0265","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1365-2141.2004.05094.x","article-title":"Tumour lysis syndrome: new therapeutic strategies and classification","volume":"127","author":"Cairo","year":"2004","journal-title":"Br J Haematol"},{"key":"10.1016\/j.leukres.2015.02.001_bib0270","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1056\/NEJMoa1215637","article-title":"Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia","volume":"369","author":"Byrd","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.leukres.2015.02.001_bib0275","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1200\/JCO.2012.42.7906","article-title":"Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed\/refractory B-cell malignancies","volume":"31","author":"Advani","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.leukres.2015.02.001_bib0280","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11899-012-0147-9","article-title":"Ibrutinib (PCI-32765), the first BTK (Bruton's Tyrosine Kinase) inhibitor in clinical trials","volume":"8","author":"Brown","year":"2013","journal-title":"Curr Hematol Malig Rep"},{"key":"10.1016\/j.leukres.2015.02.001_bib0285","doi-asserted-by":"crossref","first-page":"4684","DOI":"10.1182\/blood-2012-05-423194","article-title":"Emerging role of kinase-targeted strategies in chronic lymphocytic leukemia","volume":"120","author":"Wiestner","year":"2012","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.leukres.2015.02.001_bib0290","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1016\/j.leukres.2013.06.006","article-title":"Cyclophosphamide, alvocidib (flavopiridol), and rituximab, a novel feasible chemoimmunotherapy regimen for patients with high-risk chronic lymphocytic leukemia","volume":"Oct;37","author":"Stephens","year":"2013","journal-title":"Leuk Res"},{"key":"10.1016\/j.leukres.2015.02.001_bib0295","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1200\/JCO.2009.24.1570","article-title":"Flavopiridol, fludarabine, and rituximab in mantle cell lymphoma and indolent B-cell lymphoproliferative disorders","volume":"28","author":"Lin","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.leukres.2015.02.001_bib0300","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1182\/blood-2011-12-400184","article-title":"ER stress and autophagy: new discoveries in the mechanism of action and drug resistance of the cyclin-dependent kinase inhibitor flavopiridol","volume":"120","author":"Mahoney","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2015.02.001_bib0305","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1158\/1078-0432.CCR-12-1092","article-title":"A pharmacokinetic\/pharmacodynamic model of tumor lysis syndrome in chronic lymphocytic leukemia patients treated with flavopiridol","volume":"19","author":"Ji","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.leukres.2015.02.001_bib0310","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1056\/NEJM200012283432602","article-title":"Genomic aberrations and survival in chronic lymphocytic leukemia","volume":"343","author":"Dohner","year":"2000","journal-title":"N Engl J Med"}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212615000338?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212615000338?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,8,29]],"date-time":"2020-08-29T19:33:04Z","timestamp":1598729584000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212615000338"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,5]]},"references-count":31,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2015,5]]}},"alternative-id":["S0145212615000338"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2015.02.001","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2015,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Final results of EFC6663: A multicenter, international, phase 2 study of alvocidib for patients with fludarabine-refractory chronic lymphocytic leukemia","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2015.02.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}